David Colpman

David Colpman is currently an Independent Director at Elutia, Inc. since 2022.
Holds director positions at HighCape Capital Acquisition Corp.
II and Oak Hill Bio Corp.
since 2022.
Member of the Royal Pharmaceutical Society of Great Britain.
Advisor at HighCape Partners Management LLC and Science Creates Ventures LLP.
Formerly Director at HRA Pharma Development SARL from 2016 to 2022.
Non-Executive Director at Organon R&D Finland Oy.
Independent Director at HighCape Capital Acquisition Corp.
from 2020 to 2021.
Independent Director at Orexo AB from 2015 to 2022.
Senior Vice President at Shire Plc from 2012 to 2014.
Principal at GlaxoWellcome from 1997 to 1999.
Principal at Purdue Pharma (Canada) in 2015.
Partner at Colpman Consulting Ltd. from 2014 to 2020.
Completed undergraduate degree at the University of Portsmouth in 1984.